Alps Advisors Inc. bought a new position in Calithera Biosciences Inc (NASDAQ:CALA) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 39,313 shares of the biotechnology company’s stock, valued at approximately $328,000. Alps Advisors Inc. owned approximately 0.11% of Calithera Biosciences at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of CALA. Schwab Charles Investment Management Inc. lifted its stake in Calithera Biosciences by 249.3% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 71,600 shares of the biotechnology company’s stock worth $1,064,000 after purchasing an additional 51,100 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Calithera Biosciences by 230.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 108,102 shares of the biotechnology company’s stock valued at $1,605,000 after buying an additional 75,414 shares in the last quarter. Legal & General Group Plc purchased a new stake in shares of Calithera Biosciences during the 2nd quarter valued at $120,000. Wells Fargo & Company MN raised its position in shares of Calithera Biosciences by 705.3% during the 2nd quarter. Wells Fargo & Company MN now owns 26,832 shares of the biotechnology company’s stock valued at $399,000 after buying an additional 23,500 shares in the last quarter. Finally, Alliancebernstein L.P. purchased a new stake in shares of Calithera Biosciences during the 2nd quarter valued at $899,000. Institutional investors and hedge funds own 72.89% of the company’s stock.
Calithera Biosciences Inc (NASDAQ:CALA) opened at $7.07 on Wednesday. Calithera Biosciences Inc has a twelve month low of $6.57 and a twelve month high of $20.05. The company has a market cap of $251.00, a price-to-earnings ratio of -7.15 and a beta of 2.56.
CALA has been the topic of several research reports. Zacks Investment Research upgraded shares of Calithera Biosciences from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a research report on Monday, November 6th. BidaskClub cut shares of Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research report on Saturday, December 9th. Finally, ValuEngine cut shares of Calithera Biosciences from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $17.20.
ILLEGAL ACTIVITY NOTICE: This story was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/14/alps-advisors-inc-buys-shares-of-39313-calithera-biosciences-inc-cala.html.
About Calithera Biosciences
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.